Malignant Mesothelioma

Global Malignant Mesothelioma Market to Reach US$975.2 Million by 2030

The global market for Malignant Mesothelioma estimated at US$681.2 Million in the year 2024, is expected to reach US$975.2 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of the analysis period. Growth in the Cisplatin & Combination segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$188.4 Million While China is Forecast to Grow at 5.7% CAGR

The Malignant Mesothelioma market in the U.S. is estimated at US$188.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$150.5 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Malignant Mesothelioma Market - Key Trends & Drivers Summarized

What Is Malignant Mesothelioma and Why Is It Such a Serious Health Concern?

Malignant mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs, abdomen, or heart, caused by asbestos exposure. Due to its long latency period—often several decades after exposure—mesothelioma is typically diagnosed at an advanced stage, making it a particularly difficult disease to treat. The poor prognosis associated with malignant mesothelioma, along with its limited treatment options, has made it a critical area of focus for researchers and healthcare providers. The link between occupational asbestos exposure and the development of mesothelioma has also spurred regulatory efforts to reduce exposure risks, but the disease remains a major health concern, especially for those working in industries like construction and shipbuilding.

How Are Advances in Treatment Improving Outcomes for Mesothelioma Patients?

Advancements in the treatment of malignant mesothelioma are providing new hope for patients facing this challenging diagnosis. Traditional treatment options, such as surgery, chemotherapy, and radiation therapy, have been complemented by emerging therapies that target the disease more precisely. Immunotherapy, which harnesses the body’s immune system to attack cancer cells, has shown promising results in extending survival rates for some mesothelioma patients. Additionally, targeted therapies that inhibit specific molecular pathways involved in cancer growth are under investigation, offering potential for more personalized treatment approaches. Clinical trials exploring the combination of these innovative treatments are a key focus of ongoing research, seeking to improve outcomes for patients who historically have had limited treatment options.

What Challenges Do Patients and Healthcare Providers Face in Managing Malignant Mesothelioma?

The management of malignant mesothelioma poses significant challenges, starting with the difficulty of early detection. Symptoms of mesothelioma, such as shortness of breath and chest pain, are often nonspecific and can be mistaken for other conditions, leading to delayed diagnoses. Moreover, the advanced stage at which the disease is typically detected limits treatment options and contributes to poor survival rates. Another challenge lies in the availability of specialized care, as treating mesothelioma requires a multidisciplinary approach involving oncologists, thoracic surgeons, and radiation specialists. Access to experimental therapies and clinical trials is also limited for many patients, especially those in underserved regions. Additionally, the high costs of treatment further complicate the management of this aggressive disease.

Growth in the Malignant Mesothelioma Market Is Driven by Several Factors

The growth in the malignant mesothelioma market is driven by several factors, including advancements in immunotherapy and targeted treatments, increasing research funding, and improved awareness of asbestos-related risks. As more novel therapies enter clinical trials and regulatory approvals for new drugs expand, the market for mesothelioma treatments is expected to grow. Additionally, greater emphasis on early detection and enhanced diagnostic tools is improving the chances of identifying the disease at a more treatable stage. Growing awareness about the dangers of asbestos exposure, combined with regulatory efforts to limit its use, is also driving attention to mesothelioma, creating opportunities for the development of better preventive measures and treatments.

SCOPE OF STUDY:

The report analyzes the Malignant Mesothelioma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination, Other Drug Classes)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Fresenius Kabi AG
• Merck & Co., Inc.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.